{
    "xml": "<topic id=\"PHP5255\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/busulfan\" basename=\"busulfan\" title=\"BUSULFAN\">\n<title>BUSULFAN</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_993\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/alkylating-drugs/busulfan\">Busulfan</xref>\n</p>\n<data name=\"vtmid\">2571007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_348581499\" title=\"Alkylating agents\">Alkylating agents</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n<p outputclass=\"synonyms\">Busulphan</p>\r\n</body>\n<topic id=\"PHP62858\" outputclass=\"indicationsAndDose\" rev=\"1.18\" parent=\"/drugs/busulfan\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Chronic myeloid leukaemia, induction of remission</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>60&#8239;micrograms/kg daily (max. per dose 4&#8239;mg); maintenance 0.5&#8211;2&#8239;mg daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Conditioning treatment before haematopoietic stem-cell transplantation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult local protocol).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"extremesOfBodyWeight\">\n<title>Doses at extremes of body-weight</title>\n<p>Dose may need to be calculated based on body surface area or adjusted ideal body weight in obese patients&#8212;consult product literature.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62934\" outputclass=\"importantSafetyInformation\" rev=\"1.7\" parent=\"/drugs/busulfan\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Risks of incorrect dosing of oral anti-cancer medicines</p>\n<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p>\n<p>Standards to be followed to achieve this include:</p>\n<ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62955\" outputclass=\"cautions\" rev=\"1.24\" parent=\"/drugs/busulfan\">\n<title>Cautions</title>\n<body>\r\n<section outputclass=\"cautions\">\r\n<p>\r\n<ph outputclass=\"caution\">Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>\r\n</ph>; <ph outputclass=\"caution\">high dose (antiepileptic prophylaxis required)</ph>; <ph outputclass=\"caution\">history of seizures (antiepileptic prophylaxis required)</ph>; <ph outputclass=\"caution\">ineffective once in blast crisis phase</ph>; <ph outputclass=\"caution\">previous progenitor cell transplant (increased risk of hepatic veno-occlusive disease)</ph>; <ph outputclass=\"caution\">previous radiation therapy (increased risk of hepatic veno-occlusive disease)</ph>; <ph outputclass=\"caution\">risk of second malignancy</ph>; <ph outputclass=\"caution\">three or more cycles of chemotherapy (increased risk of hepatic veno-occlusive disease)</ph>\r\n</p>\r\n </section>\r\n\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP62853\" outputclass=\"interactions\" rev=\"1.7\" parent=\"/drugs/busulfan\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (busulfan).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62809\" outputclass=\"sideEffects\" rev=\"1.35\" parent=\"/drugs/busulfan\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<title>General side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Cardiac tamponade in thalassaemia</ph>; <ph outputclass=\"sideEffect\">hepatic fibrosis</ph>; <ph outputclass=\"sideEffect\">hepatic veno-occlusive disease</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity</ph>; <ph outputclass=\"sideEffect\">hyperbilirubinaemia</ph>; <ph outputclass=\"sideEffect\">jaundice</ph>; <ph outputclass=\"sideEffect\">pneumonia</ph>; <ph outputclass=\"sideEffect\">skin hyperpigmentation</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Aplastic anaemia</ph>; <ph outputclass=\"sideEffect\">seizures</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Gynaecomastia</ph>; <ph outputclass=\"sideEffect\">myasthenia gravis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Alopecia</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">irreversible bone-marrow aplasia</ph>; <ph outputclass=\"sideEffect\">lung toxicity</ph>; <ph outputclass=\"sideEffect\">male sterility</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">premature menopause</ph>; <ph outputclass=\"sideEffect\">secondary malignancy</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"specificSideEffects\">\n<title>Specific side-effects:</title>\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<sectiondiv outputclass=\"sideEffectsWithRoutes\">\n<p outputclass=\"title\">With intravenous use</p>\n<p>\n<ph outputclass=\"sideEffect\">extravasation</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Lung toxicity</p>\n<p>Discontinue if lung toxicity develops.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Secondary malignancy</p>\n<p>Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62946\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/busulfan\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturers advise effective contraception during and for 6 months after treatment in men or women.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Alkylating drugs often severely affect gametogenesis and carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62838\" outputclass=\"pregnancy\" parent=\"/drugs/busulfan\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (teratogenic in <i>animals</i>).</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62970\" outputclass=\"breastFeeding\" parent=\"/drugs/busulfan\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Discontinue breast-feeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62887\" outputclass=\"hepaticImpairment\" parent=\"/drugs/busulfan\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>In patients with hepatic impairment, manufacturer advises regular liver function tests&#8212;consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP62764\" outputclass=\"monitoringRequirements\" parent=\"/drugs/busulfan\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor cardiac and liver function.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Frequent blood tests are necessary because excessive myelosuppression may result in irreversible bone-marrow aplasia.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP5255-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/busulfan\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76442\" title=\"Tablet\" namespace=\"/drugs/busulfan/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76447\" title=\"Solution for infusion\" namespace=\"/drugs/busulfan/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_993\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/alkylating-drugs/busulfan\" title=\"Busulfan\" count=\"1\" rel=\"link\">Busulfan</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78608\" namespace=\"/treatment-summaries/acute-porphyrias\" title=\"Acute porphyrias\" count=\"1\" rel=\"link\">Acute porphyrias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76442\" namespace=\"/drugs/busulfan/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76447\" namespace=\"/drugs/busulfan/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5255",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/busulfan",
    "basename": "busulfan",
    "title": "BUSULFAN",
    "interactants": [
        {
            "id": "bnf_int_993",
            "label": "Busulfan"
        }
    ],
    "vtmid": "2571007",
    "drugClassification": [
        "Alkylating agents"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "synonyms": [
        "Busulphan"
    ],
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Chronic myeloid leukaemia, induction of remission",
                        "html": "Chronic myeloid leukaemia, induction of remission"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "60 micrograms/kg daily (max. per dose 4 mg); maintenance 0.5&#8211;2 mg daily.",
                        "html": "<p>60&#8239;micrograms/kg daily (max. per dose 4&#8239;mg); maintenance 0.5&#8211;2&#8239;mg daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Conditioning treatment before haematopoietic stem-cell transplantation",
                        "html": "Conditioning treatment before haematopoietic stem-cell transplantation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous infusion",
                    "html": "By mouth or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult local protocol).",
                        "html": "<p>(consult local protocol).</p>"
                    }
                ]
            }
        ],
        "extremesOfBodyWeight": [
            {
                "type": "extremesOfBodyWeight",
                "title": "Doses at extremes of body-weight",
                "textContent": "Dose may need to be calculated based on body surface area or adjusted ideal body weight in obese patients&#8212;consult product literature.",
                "html": "<p>Dose may need to be calculated based on body surface area or adjusted ideal body weight in obese patients&#8212;consult product literature.</p>"
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Risks of incorrect dosing of oral anti-cancer medicines",
                "textContent": "The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.\n\nStandards to be followed to achieve this include:\n\nnon-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity; staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.",
                "html": "<p>The National Patient Safety Agency has advised (January 2008) that the prescribing and use of oral cytotoxic medicines should be carried out to the same standard as parenteral cytotoxic therapy.</p><p>Standards to be followed to achieve this include:</p><ul>\n<li>non-specialists who prescribe or administer on-going oral cytotoxic medication should have access to written protocols and treatment plans, including guidance on the monitoring and treatment of toxicity;</li>\n<li>staff dispensing oral cytotoxic medicines should confirm that the prescribed dose is appropriate for the patient. Patients should have written information that includes details of the intended oral anti-cancer regimen, the treatment plan, and arrangements for monitoring, taken from the original protocol from the initiating hospital. Staff dispensing oral cytotoxic medicines should also have access to this information, and to advice from an experienced cancer pharmacist in the initiating hospital.</li>\n</ul>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Avoid in Acute porphyrias",
                "html": "Avoid in <xref format=\"dita\" href=\"#PHP78608\" type=\"bookmark\" namespace=\"/treatment-summaries/acute-porphyrias\">Acute porphyrias</xref>",
                "references": [
                    {
                        "id": "PHP78608",
                        "label": "Acute porphyrias"
                    }
                ]
            },
            {
                "type": "cautions",
                "textContent": "high dose (antiepileptic prophylaxis required)",
                "html": "high dose (antiepileptic prophylaxis required)"
            },
            {
                "type": "cautions",
                "textContent": "history of seizures (antiepileptic prophylaxis required)",
                "html": "history of seizures (antiepileptic prophylaxis required)"
            },
            {
                "type": "cautions",
                "textContent": "ineffective once in blast crisis phase",
                "html": "ineffective once in blast crisis phase"
            },
            {
                "type": "cautions",
                "textContent": "previous progenitor cell transplant (increased risk of hepatic veno-occlusive disease)",
                "html": "previous progenitor cell transplant (increased risk of hepatic veno-occlusive disease)"
            },
            {
                "type": "cautions",
                "textContent": "previous radiation therapy (increased risk of hepatic veno-occlusive disease)",
                "html": "previous radiation therapy (increased risk of hepatic veno-occlusive disease)"
            },
            {
                "type": "cautions",
                "textContent": "risk of second malignancy",
                "html": "risk of second malignancy"
            },
            {
                "type": "cautions",
                "textContent": "three or more cycles of chemotherapy (increased risk of hepatic veno-occlusive disease)",
                "html": "three or more cycles of chemotherapy (increased risk of hepatic veno-occlusive disease)"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (busulfan).",
                "html": "<p>Appendix 1 (busulfan).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Cardiac tamponade in thalassaemia",
                        "html": "Cardiac tamponade in thalassaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatic fibrosis",
                        "html": "hepatic fibrosis",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatic veno-occlusive disease",
                        "html": "hepatic veno-occlusive disease",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hepatotoxicity",
                        "html": "hepatotoxicity",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "hyperbilirubinaemia",
                        "html": "hyperbilirubinaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "jaundice",
                        "html": "jaundice",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "pneumonia",
                        "html": "pneumonia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "skin hyperpigmentation",
                        "html": "skin hyperpigmentation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Aplastic anaemia",
                        "html": "Aplastic anaemia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "seizures",
                        "html": "seizures",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Gynaecomastia",
                        "html": "Gynaecomastia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "myasthenia gravis",
                        "html": "myasthenia gravis",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Alopecia",
                        "html": "Alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "irreversible bone-marrow aplasia",
                        "html": "irreversible bone-marrow aplasia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "lung toxicity",
                        "html": "lung toxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "male sterility",
                        "html": "male sterility",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "premature menopause",
                        "html": "premature menopause",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "secondary malignancy",
                        "html": "secondary malignancy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "specific": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "sideEffectsWithRoutes",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "With intravenous use",
                            "html": "With intravenous use",
                            "routes": [
                                "intravenous"
                            ]
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Lung toxicity",
                "textContent": "Discontinue if lung toxicity develops.",
                "html": "<p>Discontinue if lung toxicity develops.</p>"
            },
            {
                "type": "advice",
                "title": "Secondary malignancy",
                "textContent": "Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.",
                "html": "<p>Prolonged use of alkylating drugs, particularly when combined with extensive irradiation, is associated with a marked increase in the incidence of acute non-lymphocytic leukaemia.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturers advise effective contraception during and for 6 months after treatment in men or women.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins; manufacturers advise effective contraception during and for 6 months after treatment in men or women.</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Alkylating drugs often severely affect gametogenesis and carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Alkylating drugs often severely affect gametogenesis and carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (teratogenic in animals).\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Avoid (teratogenic in <i>animals</i>).</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Discontinue breast-feeding.",
                "html": "<p>Discontinue breast-feeding.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution.",
                "html": "<p>Manufacturer advises caution.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "In patients with hepatic impairment, manufacturer advises regular liver function tests&#8212;consult product literature.",
                "html": "<p>In patients with hepatic impairment, manufacturer advises regular liver function tests&#8212;consult product literature.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor cardiac and liver function.",
                "html": "<p>Monitor cardiac and liver function.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Frequent blood tests are necessary because excessive myelosuppression may result in irreversible bone-marrow aplasia.",
                "html": "<p>Frequent blood tests are necessary because excessive myelosuppression may result in irreversible bone-marrow aplasia.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76442",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76447",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_993",
                "label": "Busulfan",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78608",
                "label": "Acute porphyrias",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76442",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76447",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}